probucol has been researched along with Vascular Diseases in 3 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant." | 1.33 | The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. ( Malinin, A; Scott, R; Serebruany, V, 2006) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serebruany, V | 2 |
| Malinin, A | 2 |
| Qiu, FH | 1 |
| Xu, XC | 1 |
| Kunsch, C | 1 |
| Scott, R | 2 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 1 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
1 trial available for probucol and Vascular Diseases
| Article | Year |
|---|---|
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Topics: Adolescent; Adult; Aged; Biomarkers; Cells, Cultured; Coronary Artery Disease; Dose-Response Relatio | 2009 |
2 other studies available for probucol and Vascular Diseases
| Article | Year |
|---|---|
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Topics: Adult; Antigens, CD; Antioxidants; Baltimore; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2006 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |